322 related articles for article (PubMed ID: 35770040)
1. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Deshpande A; Munoz J
Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
3. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
5. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Muñoz J; Paludo J; Sarosiek S; Castillo JJ
Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
[TBL] [Abstract][Full Text] [Related]
7. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
8. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
Varettoni M; Matous JV
Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
[TBL] [Abstract][Full Text] [Related]
9. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
[TBL] [Abstract][Full Text] [Related]
10. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
11. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
[TBL] [Abstract][Full Text] [Related]
12. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
13. Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
Wolska-Washer A; Robak T
Front Oncol; 2023; 13():1130595. PubMed ID: 37035197
[TBL] [Abstract][Full Text] [Related]
14. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
Dimopoulos M; Sanz RG; Lee HP; Trneny M; Varettoni M; Opat S; D'Sa S; Owen RG; Cull G; Mulligan S; Czyz J; Castillo JJ; Motta M; Siddiqi T; Gironella Mesa M; Granell Gorrochategui M; Talaulikar D; Zinzani PL; Askari E; Grosicki S; Oriol A; Rule S; Kloczko J; Tedeschi A; Buske C; Leblond V; Trotman J; Chan WY; Michel J; Schneider J; Tan Z; Cohen A; Huang J; Tam CS
Blood Adv; 2020 Dec; 4(23):6009-6018. PubMed ID: 33284944
[TBL] [Abstract][Full Text] [Related]
15. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
Moore DC
J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
[TBL] [Abstract][Full Text] [Related]
16. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
[TBL] [Abstract][Full Text] [Related]
18. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract][Full Text] [Related]
19. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
[TBL] [Abstract][Full Text] [Related]
20. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
